Tranexamic acid in subarachnoid hemorrhage. A double-blind study

Area of Science:

• Neurology
• Pharmacology

Background:

• Subarachnoid hemorrhage (SAH) is a critical neurological condition.
• Preventing re-bleeding and improving outcomes in SAH is a major clinical challenge.

Purpose of the Study:

• To evaluate the efficacy and safety of intravenous tranexamic acid in patients with subarachnoid hemorrhage.
• To determine if tranexamic acid reduces re-bleeding rates, morbidity, or mortality.

Main Methods:

• A double-blind, placebo-controlled trial involving 64 patients with subarachnoid hemorrhage.
• Patients received either intravenous tranexamic acid (6 g daily) or placebo.
• Treatment continued until aneurysm surgery or for up to 21 days post-hemorrhage.

Main Results:

• No significant differences were observed in re-bleeding rates between the tranexamic acid and placebo groups.
• Morbidity and mortality rates were comparable between the two treatment arms.
• No thromboembolic complications were reported in either group, suggesting a favorable safety profile.

Conclusions:

• The study findings do not support the routine use of intravenous tranexamic acid at a daily dose of 6 g for managing subarachnoid hemorrhage.
• Further research may be needed to explore different dosages or patient subgroups, but current evidence is negative.